Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 897-906

  Lee, W C ^a   Conner, C ^b   Hammer, M ^c  

^a IQVIA   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Cost effectiveness; Glimepiride; Liraglutide; Rosiglitazone; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; ROSIGLITAZONE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 79954522075     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.559444     Document Type: Article

References (65)

1. U.S. Department of Health and Human Services. National diabetes fact sheet,. 2007. Atlanta, GA; 2008. http://www.cdc.gov/diabetes/pubs/pdf/ ndfs-2007.pdf [Accessed February 18, 2010].
2. Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303. Epub January 14, 2010.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
6. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009(Suppl 1):S13-61.
7. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
8. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
9. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008;358:2633-5. (Pubitemid 351831366)
10. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3. (Pubitemid 351831365)
11. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67.
12. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
13. ACE/AACE Diabetes Road Map Task Force. Road map to achieve glycemic goals: Naive to therapy (Type 2). 2008.
14. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-43. (Pubitemid 44903747)
15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
16. Avandia Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; 2008.
17. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741-53. (Pubitemid 47347350)
18. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51.
19. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. (Pubitemid 47403105)
20. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70. (Pubitemid 41751172)
21. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72. (Pubitemid 44156663)
22. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006;28:96-108.
23. Exenatide Prescribing Information. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008.
24. Novo Nordisk Endocrine and Metabolic Drug Advisory Committee. Liraglutide (injection) for the Treatment of Patients with Type 2 Diabetes: NDA 22-341 Briefing Document. 2009.
25. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373:473-81.
26. Novo Nordisk Data on File. 2009.
27. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
28. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
29. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
30. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon- like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\+TZD). Diabetes Care 2009;32:1224-30.
31. Sullivan SD, Alfonso-Cristancho R, Conner C, et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol 2009;8:12.
32. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26.
33. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40. (Pubitemid 39349906)
34. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5.
35. Berger ML, Bingefors K, Hedblom EC, et al. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research.
36. Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007; 27:1102-10. (Pubitemid 47173656)
37. U.K. Prospective Diabetes Study (UKPDS) Group. U.K. prospective diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
38. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71. (Pubitemid 46919772)
39. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. (Pubitemid 47403105)
40. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
41. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the mrisk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81. (Pubitemid 351664507)
42. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
43. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81. (Pubitemid 30090804)
44. U.S. Department of Labor BoLS. Consumer Price Index for the Healthcare Sector, 2010.
45. ISPOR Global Health Care Systems Road Map. Reimbursement Processes Around the World. International Society for Pharmacoeconomics and Outcomes Research 2009. Available from: http://www.ispor.org/ HTARoadMaps.
46. Medi-Span- Wolters Kluwer. http://www.medi-span.com.
47. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30. (Pubitemid 40360759)
48. Technology appraisal guidance on the use of long-acting insulin analogues, Report No. 53, 2002. National Institute for Clinical Excellence (NICE) 2009. Available from: URL: http://guidance.nice.org.uk/.
49. Currie CJ, Morrissey M, Peters JR. The impact on health-related quality of life (EQ-5D index) in people with type 1 diabetes who experience severe hypoglycaemia. Diabetologia 2005;48:A292-3.
50. Tunis SL, Minshall ME. Self monitoring of blood glucose in type 2 diabetes: Cost-effectiveness in the United States. Am J Manag Care 2008;14:131-40. (Pubitemid 351367356)
51. Carter A, Parker MM, Moffett HZ, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29:1757-63. (Pubitemid 44156626)
52. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40. (Pubitemid 27384638)
53. Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997; 126:337-46. (Pubitemid 27102517)
54. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127:955-65. (Pubitemid 27516606)
55. Mark DB, Simons TA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis. Am Heart J 1999;137:S38-40.
56. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982;1:61-80.
57. Tan-Torres Edejer T, Baltussen R, Adam T et al., eds. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: World Health Organization, 2003. WHO. http://www.who.int/choice/publications/.
58. Karter AJ, Moffet HH, Liu J, et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care 2005;11:262-70. (Pubitemid 40569749)
59. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-53.
60. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6.
61. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
62. Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69. (Pubitemid 350246602)
63. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-4.
64. Novo Nordisk. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes (LEAD-1). Clinical Trials Gov 2009. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00318422?term=liraglutide&rank=15.
65. George J, Hannah S, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc Ther 2009;27:83-8